<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00346684</url>
  </required_header>
  <id_info>
    <org_study_id>RIPL</org_study_id>
    <nct_id>NCT00346684</nct_id>
  </id_info>
  <brief_title>Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)</brief_title>
  <official_title>Rituximab in Primary LPHD (RIPL) - First Line Therapy for Patients With Lymphocyte Predominant Hodgkin´s Disease (LPHD) in Clinical Stage IA Using the Monoclonal Anti-CD20 Antibody Rituximab.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cologne</source>
  <brief_summary>
    <textblock>
      First line therapy for patients with Lymphocyte predominant Hodgkin´s Disease (LPHD) in
      clinical stage IA using the monoclonal anti-CD20 antibody rituximab
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Lymphocyte Predominant Hodgkin´s Lymphoma (LPHD)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  lymphocyte predominant Hodgkin´s lymphoma (histologically proven)

          -  clinical stage IA (without risk factors: large mediastinal mass, extranodal
             involvement, ESR &gt; 50mm/h)

          -  age 18 - 75

          -  WHO performance status 0-3

          -  normal organ function

          -  written informed consent

        Exclusion Criteria:

          -  classical Hodgkin´s lymphoma

          -  composite lymphoma

          -  leucocytes &lt; 3000/µl

          -  thrombocytes &lt; 100.000/µl
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Engert</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitiy of Cologne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2006</study_first_submitted>
  <study_first_submitted_qc>June 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2006</study_first_posted>
  <last_update_submitted>August 11, 2008</last_update_submitted>
  <last_update_submitted_qc>August 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2008</last_update_posted>
  <keyword>Lymphoma</keyword>
  <keyword>LPHD</keyword>
  <keyword>Rituximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

